🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the battle against superbug strains of the pathogen, according to scientists.

An International Public Health Issue

The sexually transmitted infection are increasing worldwide, with estimates suggesting more than 82 million infections per year. Particularly high rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to develop it.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Data and Global Access

Based on results detailed in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which uses an injection and a pill. The research involved over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in a wide range of developing nations.

Medical professionals directly involved have voiced optimism. Access to a single-dose, oral treatment like this is hailed as a "revolutionary step" for managing the epidemic. This is considered crucial to reduce the burden of the disease for patients and to stop the proliferation of untreatable gonorrhoea around the world.